Synergism in concomitant chemoradiotherapy of cisplatin and oxaliplatin and their liposomal formulation in the human colorectal cancer HCT116 model

Anticancer Research

Volumn 32, Issue 10, 2012, Pages 4395-4404

  Tippayamontri, Thititip ^a   Kotb, Rami ^b   Paquette, Benoit ^a   Sanche, Léon ^a  

^a UNIVERSITY OF SHERBROOKE   (Canada)

^b CENTRE HOSPITALIER UNIVERSITAIRE DE SHERBROOKE   (Canada)

Author keywords

Chemoradiotherapy; Cisplatin; Colorectal cancer cells; HCT116; Lipoplatin ; Liposomal formulation; Lipoxal ; Oxaliplatin; Synergism

Indexed keywords

CISPLATIN; LIPOSOME; OXALIPLATIN;

ARTICLE; CANCER CHEMOTHERAPY; CANCER INHIBITION; CELL CYCLE G2 PHASE; COLORECTAL CANCER; CONTROLLED STUDY; DRUG FORMULATION; DRUG MECHANISM; DRUG POTENTIATION; GAMMA RADIATION; IC 50; PRIORITY JOURNAL;

ANTINEOPLASTIC AGENTS; CHEMORADIOTHERAPY; CISPLATIN; COLORECTAL NEOPLASMS; DRUG SYNERGISM; GAMMA RAYS; HCT116 CELLS; HUMANS; LIPOSOMES; ORGANOPLATINUM COMPOUNDS;

EID: 84867827733     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. Argiris A: Update on chemoradiotherapy for head and neck cancer. Curr Opin Oncol 14: 323-329, 2002.
2. O'Rourke N, Roque I Figuls M, Farre Bernado N and Macbeth F: Concurrent chemoradiotherapy in non-small cell lung cancer. Cochrane Database Syst Rev 6: CD002140, 2010.
3. Robertson JM: The role of radiation therapy for colorectal cancer. Gastroenterol Clin North Am 37: 269-285, 2008.
4. Wang ML and Foo KF: Adjuvant chemoradiotherapy for highrisk pancreatic cancer. Singapore Med J 50: 43-48, 2009.
5. Dewit L: Combined treatment of radiation and cisdiamminedichloroplatinum (II): A review of experimental and clinical data. Int J Radiat Oncol Biol Phys 13: 403-426, 1987.
6. Bellamy AS and Hill BT: Interactions between clinically effective antitumor drugs and radiation in experimental systems. Biochim Biophys Acta 738: 125-166, 1984. (Pubitemid 15153302)
7. Culy CR, Clemett D and Wiseman LR: Oxaliplatin. A review of its pharmacological properties and clinical efficacy in metastatic colorectal cancer and its potential in other malignancies. Drugs 60: 895-924, 2000.
8. Kim GP and Erlichman C: Oxaliplatin in the treatment of colorectal cancer. Expert Opin Drug Metab Toxicol 3: 281-294, 2007. (Pubitemid 47316043)
9. Marcu L, van Doorn T and Olver I: Cisplatin and radiotherapy in the treatment of locally advanced head and neck cancer - a review of their cooperation. Acta Oncol 42: 315-325, 2003. (Pubitemid 36851149)
10. Zheng Y, Hunting DJ, Ayotte P and Sanche L: Role of secondary low-energy electrons in the concomitant chemoradiation therapy of cancer. Phys Rev Lett 100: 198101, 2008.
11. Gorodetsky R, Levy-Agababa F, Mou X and Vexler AM: Combination of cisplatin and radiation in cell culture: Effect of duration of exposure to drug and timing of irradiation. Int J Cancer 75: 635-642, 1998. (Pubitemid 28094113)
12. Tippayamontri T, Kotb R, Paquette B and Sanche L: Cellular uptake and cytoplasm/DNA distribution of cisplatin and oxaliplatin and their liposomal formulation in human colorectal cancer cell HCT116. Invest New Drugs 29: 1321-1327, 2011.
13. Boulikas T and Vougiouka M: Cisplatin and platinum drugs at the molecular level. (review). Oncol Rep 10: 1663-1682, 2003.
14. Shen DW, Goldenberg S, Pastan I and Gottesman MM: Decreased accumulation of [14C]carboplatin in human cisplatin-resistant cells results from reduced energy-dependent uptake. J Cell Physiol 183: 108-116, 2000. (Pubitemid 30130231)
15. Yang AD, Fan F, Camp ER, van Buren G, Liu W, Somcio R, Gray MJ, Cheng H, Hoff PM and Ellis LM: Chronic oxaliplatin resistance induces epithelial-to-mesenchymal transition in colorectal cancer cell lines. Clin Cancer Res 12: 4147-4153, 2006.
16. Fuertes MA, Alonso C and Perez JM: Biochemical modulation of cisplatin mechanisms of action: Enhancement of antitumor activity and circumvention of drug resistance. Chem Rev 103:645-662, 2003.
17. Masek V, Anzenbacherova E, Machova M, Brabec V and Anzenbacher P: Interaction of antitumor platinum complexes with human liver microsomal cytochromes P450. Anticancer Drugs 20: 305-311, 2009.
18. Fedier A, Poyet C, Perucchini D, Boulikas T and Fink D: MLH1-deficient tumor cells are resistant to lipoplatin, but retain sensitivity to lipoxal. Anticancer Drugs 17: 315-323, 2006.
19. Koukourakis MI, Giatromanolaki A, Pitiakoudis M, Kouklakis G, Tsoutsou P, Abatzoglou I, Panteliadou M, Sismanidou K, Sivridis E and Boulikas T: Concurrent liposomal cisplatin (lipoplatin), 5-fluorouracil and radiotherapy for the treatment of locally advanced gastric cancer: A phase I/II study. Int J Radiat Oncol Biol Phys, 2010.
20. Chou TC and Talalay P: Quantitative analysis of dose-effect relationships: The combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 22: 27-55, 1984.
21. Chou TC: Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies. Pharmacol Rev 58: 621-681, 2006.
22. Wallner KE and Li GC: Effect of cisplatin resistance on cellular radiation response. Int J Radiat Oncol Biol Phys 13: 587-591, 1987. (Pubitemid 17069656)
23. Bentzen SM, Harari PM and Bernier J: Exploitable mechanisms for combining drugs with radiation: Concepts, achievements and future directions. Nat Clin Pract Oncol 4: 172-180, 2007. (Pubitemid 46358854)
24. Fedier A, Poyet C, Perucchini D, Boulikas T and Fink D: MLH1-deficient tumor cells are resistant to lipoplatin, but retain sensitivity to lipoxal. Anticancer Drugs 17: 315-323, 2006.
25. Arango D, Wilson AJ, Shi Q, Corner GA, Aranes MJ, Nicholas C, Lesser M, Mariadason JM and Augenlicht LH: Molecular mechanisms of action and prediction of response to oxaliplatin in colorectal cancer cells. Br J Cancer 91: 1931-1946, 2004. (Pubitemid 40065523)
26. Hata T, Yamamoto H, Ngan CY, Koi M, Takagi A, Damdinsuren B, Yasui M, Fujie Y, Matsuzaki T, Hemmi H, Xu X, Kitani K, Seki Y, Takemasa I, Ikeda M, Sekimoto M, Matsuura N and Monden M: Role of p21waf1/cip1 in effects of oxaliplatin in colorectal cancer cells. Mol Cancer Ther 4: 1585-1594, 2005. (Pubitemid 41556442)
27. Seiwert TY, Salama JK and Vokes EE: The concurrent chemoradiation paradigm - general principles. Nat Clin Pract Oncol 4: 86-100, 2007. (Pubitemid 46189538)
28. Yang LX, Douple EB and Wang HJ: Irradiation enhances cellular uptake of carboplatin. Int J Radiat Oncol Biol Phys 33:641-646, 1995.
29. Yang Z, Faustino PJ, Andrews PA, Monastra R, Rasmussen AA, Ellison CD and Cullen KJ: Decreased cisplatin/DNA adduct formation is associated with cisplatin resistance in human head and neck cancer cell lines. Cancer Chemother Pharmacol 46:255-262, 2000.
30. Charest G, Paquette B, Fortin D, Mathieu D and Sanche L: Concomitant treatment of F98 glioma cells with new liposomal platinum compounds and ionizing radiation. J Neurooncol 97:187-193, 2010.
31. Gorodetsky R, Levy-Agababa F, Mou X and Vexler AM: Combination of cisplatin and radiation in cell culture: Effect of duration of exposure to drug and timing of irradiation. Int J Cancer 75: 635-642, 1998. (Pubitemid 28094113)
32. Britten RA and Warenius HM: De novo cisplatinum resistance does not influence cellular radiosensitivity. Eur J Cancer 29A:1315-1320, 1993. (Pubitemid 23169905)
33. Hoffe SE, Shridhar R and Biagioli MC: Radiation therapy for rectal cancer: Current status and future directions. Cancer Control 17: 25-34, 2010.